Key Patient Factors in Determining an Optimal Biologic Therapy
An expert rheumatologist highlights the billing process for patients receiving biologic therapies, as well as a study that highlights patient reported outcomes in patients with inflammatory arthritis utilizing intravenous biologics.
Video content above is prompted by the following questions:
- What is the difference in the billing process with IV and subQ therapies? What are the pros and cons of each?
- Patient reported outcomes have been assessed for patients with inflammatory arthritis utilizing IV biologics. What did this study demonstrate and does it impact your clinical practice?
Newsletter
Get the latest industry news, event updates, and more from Managed healthcare Executive.
K-Cast Written Summary. Key Patient Considerations for Use of Intravenous and Subcutaneous Therapies
October 7th 2024Jill Zouzoulas, M.D., of Tryon Medical Partners in Charlotte, North Carolina, and Jennifer Seminerio, M.D., of University of Southern Florida Health in Tampa, Florida, discussed the biologics and the pros and cons of the intravenous and subcutaneous delivery methods in Managed Healthcare Executive’s K-Cast video series.
Read More
Value-Based Decision-Making in Metastatic Breast Cancer
September 16th 2021In this Managed Healthcare Executive® KCast, Ian Krop, M.D., Ph.D., oncologist and associate professor of medicine at Dana-Farber Cancer Institute in Boston, and Debra Patt, M.D., Ph.D., MBA, executive vice president at Texas Oncology in Austin, provide key insights into the value-based care model for patients with HER2-positive metastatic breast cancer (mBC). This article summarizes the highlights of the discussion.
Read More
